Share this video  

SABCS 2022 | Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapy

Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, discusses some of the remaining questions regarding the use of CDK4/6 inhibitors in the adjuvant setting for breast cancer. Currently, there only one agent used within this setting, abemaciclib, for high-risk patients. Whether patients who are at low-risk benefit from CDK4/6 inhibitors is unknown, as well as the optimal duration of treatment. The Phase III NATALEE (NCT03701334) trial is investigating the use of ribociclib With endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer over three years, which may help to identify a superior duration of treatment. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.